Eaton's Innovative Safety Solutions Help Accelerate Electrified Vehicle Transition
Intelligent power management company Eaton today announced its comprehensive suite of safety-focused electrified vehicle (EV) technologies will be on display June 18-20 in Hall 10-A36 at The Battery Show Europe in Stuttgart, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611322422/en/
Eaton plans to show its suite of safety-focused electrified vehicle (EV) technologies June 18-20 at The Battery Show Europe in Stuttgart, Germany. (Photo: Business Wire)
“While EV adoption continues to increase, we are helping our global customers meet the growing demand with innovative new technologies,” said Mark Schneider, president, Eaton’s eMobility business. “Safety is always a priority, whether the vehicle is powered by gasoline or electricity, and our EV solutions ensure occupants and the vehicle itself remain secure.”
Breaktor a pioneering high-voltage EV protection device
Eaton’s Breaktor® circuit protection technology combines the function of fuses, pyro switches, and contactors into a single coordinated and resettable device. As electric vehicle power levels increase, Breaktor solves the ever-increasing coordination challenge between fuses and contactors and offers extremely fast, safe and reliable protection for high-power battery and inverter systems.
3-in-1 battery vent valve improves battery pack leak testing
Eaton’s 3-in-1 battery vent valve is the first-to-market solution that is capable of three unique functions. In addition to passive and active venting, to provide overpressure relief for the vehicle’s battery pack, it includes an industry first battery-case leak-check mechanism.
It can open up during testing, allowing battery makers to completely leak-check the fully assembled battery pack with the valve in place. This provides customers with the peace of mind that all sealing surfaces of the battery pack are fully tested against water ingress. This Eaton-developed technology improves the safety of vehicles during normal operation and in the event of flooding situations.
The vent valve is precisely and flexibly designed to meet specific opening pressures and optimize venting. Its spring-based actuation technology allows Eaton to accommodate different opening pressure requirements with the same valve design to drive economies of scale.
Fuel tank isolation valve releases pressure in hybrid-electric vehicles
Eaton’s next-generation fuel tank isolation valve (FTIV) releases pressure in the gas tank of a hybrid-electric vehicle since the gas engine in a hybrid vehicle does not operate continuously. Pressure has to be released when the vehicle is in electric mode, and when refueling it’s important the tank is depressurized to avoid spit back.
High Power Lock Box terminals provide protection against the elements
Eaton’s High Power Lock Box (HPLB) terminals, which serve as the interface to a conductor and create a point where external circuits can be connected, are ideal for current and future EV solutions. They have numerous benefits over competitive solutions, including a space-saving profile, superior performance, cost savings, and reduced manufacturing complexity. They also provide efficiency, reliability and protection against the elements.
Eaton Bussmann series fuses optimized for high-powered electrified vehicles
Eaton Bussmann® series fuses feature ratings of up to 1,000 volts of direct current (VDC) and up to 600 amps, enabling them to meet the requirements for use in high-powered EVs.
Eaton's hybrid and EV fuses are designed to manage and protect the charging systems of electric commercial, passenger and high-performance vehicles such as sports cars and large sport-utility vehicles.
Learn more about Eaton’s EV solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611322422/en/
Contacts
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 03:15:00 EET | Press release
Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 23:10:00 EET | Press release
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerstone of IonQ’s global strategy,” said Niccolo de Masi, Chairman and CEO of IonQ. “QuantumBasel continues to be a critical innovation node for our company as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom